Open AccessIntravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells
Author(s) -
Faezzah Baharom,
Ramiro A. Ramirez-Valdez,
Kennedy K S Tobin,
Hidehiro Yamane,
Charles–Antoine Dutertre,
Ahad Khalilnezhad,
Glennys V. Reynoso,
Vincent Coble,
Geoffrey M. Lynn,
Matthew P. Mulè,
Andrew J. Martins,
John P. Finnigan,
Xiao Meng Zhang,
Jessica A. Hamerman,
Nina Bhardwaj,
John S. Tsang,
Heather D. Hickman,
Florent Ginhoux,
Andrew S. Ishizuka,
Robert A. Seder
Publication year - 2020
Publication title -
nature immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 9.074
H-Index - 388
eISSN - 1529-2916
pISSN - 1529-2908
DOI - 10.1038/s41590-020-00810-3
Subject(s) - cytotoxic t cell , cd8 , biology , stem cell , immunology , t cell , adjuvant , antigen presenting cell , cancer research , antigen , microbiology and biotechnology , immune system , genetics , in vitro
Personalized cancer vaccines are a promising approach for inducing T cell immunity to tumor neoantigens. Using a self-assembling nanoparticle vaccine that links neoantigen peptides to a Toll-like receptor 7/8 agonist (SNP-7/8a), we show how the route and dose alter the magnitude and quality of neoantigen-specific CD8 + T cells. Intravenous vaccination (SNP-IV) induced a higher proportion of TCF1 + PD-1 + CD8 + T cells as compared to subcutaneous immunization (SNP-SC). Single-cell RNA sequencing showed that SNP-IV induced stem-like genes (Tcf7, Slamf6, Xcl1) whereas SNP-SC enriched for effector genes (Gzmb, Klrg1, Cx3cr1). Stem-like cells generated by SNP-IV proliferated and differentiated into effector cells upon checkpoint blockade, leading to superior antitumor response as compared to SNP-SC in a therapeutic model. The duration of antigen presentation by dendritic cells controlled the magnitude and quality of CD8 + T cells. These data demonstrate how to optimize antitumor immunity by modulating vaccine parameters for specific generation of effector or stem-like CD8 + T cells.